The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Optimal use of antihypertensive agents in management of bevacizumab-associated hypertension.
Mitsukuni Suenaga
Disclosure not yet available
Hiroshi Imada
Disclosure not yet available
Eri Nakamoto
Disclosure not yet available
Satoshi Matsusaka
Disclosure not yet available
Toshiyasu Watanabe
Disclosure not yet available
Yoshimasa Kawazoe
Disclosure not yet available
Eiji Shinozaki
Disclosure not yet available
Keisho Chin
Disclosure not yet available
Nobuyuki Mizunuma
Disclosure not yet available
Kiyohiko Hatake
Disclosure not yet available